The Efficacy and Safety of MK0724 IV for Improvement of Neurological Damage and Recovery From Middle Cerebral Artery Ischemic Stroke (0724-018)

A Phase IIa Randomized, Double-Blind, Parallel-Groups, Placebo Controlled Clinical Trial to Study the Efficacy and Safety of MK0724 Intravenous Infusion on the Amelioration of Neurological Damage and Recovery From Middle Cerebral Artery Ischemic Stroke

Status

Terminated

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00401310

Enrollment

150

Registered

2006-11-20

Start date

2007-07-31

Completion date

2009-01-31

Last updated

2015-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Middle Cerebral Artery Stroke

Brief summary

The safety and efficacy of MK0724 will be assessed in patients with acute middle cerebral artery stroke using the Action Reach Arm Test (ARAT). This test allows measurement of a specific functional deficit and subsequent recovery correlating with the specific area of stroke in the brain.

Interventions

DRUGComparator: Placebo

Placebo IV infusions 1hr/daily over 7 days.

DRUGComparator: MK0724

MK0724 8 mg/kg/hr 1 hr/daily over 7 days.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* 18-80 yrs of age inclusive * Patient is able to receive IV infusion 8-36 hours after stroke onset * Baseline NIHSS of 6-18 inclusive

Exclusion criteria

* Patient had another stroke within 3 months preceding current stroke, patient's stroke is of origin other than MCA (e.g., non-ischemic, hemorrhage), significant cerebral edema, abnormal liver enzymes and abnormal renal and hepatic functions

Design outcomes

Primary

Measure	Time frame
Action Research Arm Test score	At 90 days

Secondary

Measure	Time frame
Scores on the Stroke Arm Strength question, modified Rankin, and Barthel Index.	At 90 days

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026